by our All Dac; you, call joined and on our afternoon, Jacobson; good Whitaker. our Officer, Andreas Nadia I'm Accounting right. Grauer; Regulatory everyone. Chief Chief our and our President, Thank Peter, Clinical Melfi; Medical Officer; Steve Mike Officer, Chief today's Commercial Cathy Vice Officer, Chief
for as further quarter as the financial the XX, of XXXX Our summary corporate provide full a remarks. December year fourth and details will follow overview today discussion include results a ended well will Mike for Mike's the of brief XXXX. a period on will update. results The then question-and-answer quarter financial of fourth our
at want you will time you. that call you company, share find of call, will frequently a that's things our we the them there join today's lot exciting happening of usual. and are longer that because to than be take those And with the to For
successfully cell one, midterm approval at soon our and or II a quarter a in into in nocturnal of are: one our glomerulopathy; stock cash value driving take our moving thrombotic MASP-X to launching significant Phase in indication. our inhibitor I stem FDA priorities earnings III of and program identified call, OMSXXXX, drivers large the PNH, long-acting in paroxysmal these X Those OMSXXX clinical runway In market; both clinical possible, shareholders; narsoplimab, in near third trial four, without two, inhibitor extending inhibitor, TA-TMA, the diluting value drug a microangiopathy, represent corporate hematopoietic priorities into CX We'll as that and to price. Phase our time. obtaining XXXX our transplant-associated MASP-X hemoglobinuria, or MASP-X three, as in X
extended XXXX. million February through First, into opportunity milestone brought with accomplished runway an in That runway DRI X was additional additional nondilutive deal in extending transaction to sales-related This Healthcare, capital our with more total $XXX dilution. cash $XX royalty an of earn of payments. the million in without
future when is two, in to All top Surgical OMIDRIA of payment million retained sold million whom of on $XXX another upfront $XXX XXXX; OMIDRIA Healthcare royalty plus payment receivables from received to stream we and from in OMIDRIA. we for a sold our late tied XXXX $XXX this in Rayner in care; reimbursement portion achieving three, milestone early DRI to of XXXX Rayner long-term million a more
nearly on beginning X payments, $XXX with to anywhere the OMIDRIA then provided XXXX, ex and January royalty million OMIDRIA the this OMIDRIA Rayner sales world addition X, string to nondilutive XX% Omeros a on years accrue retains financing. In December of to Since from in its XXXX, sales in of Omeros. ago, sale will all little Omeros over has of U.S. royalties
secure capital This to has nondilutive inflow Omeros' position. of financial helped strong
Now let's results for our fourth quarter the and both look at the financial year.
XXXX loss per our results fourth revaluation for of royalty reflection share the quarter $X.XX XXXX. $XX.X million a the million part OMIDRIA XXXX of year $X.X The loss of earned million $X.XX quarter third a net and $XXX long-term per a net in the or on to of of loss per the separate million was was third quarter per $XXX.X $X.XX share operations, $XX drug and share prior for share payment. or $XX.X of ] Based our the the for compared XXXX. [ $XX.X fourth of per loss quarter loss million and net the a of share $X.XX by net $X.XX asset compared fourth fourth of of or million quarter share driven of quarter were continuing securing $X.XX to net in of net per only the the quarter OMIDRIA by million milestone for fourth or for or Our or contract a income the
million, improvements million of represent $XX.X These $X.X and respectively.
share our For $XXX.X income the share was $XX.X or net $X.XX $X.XX full loss to year compared per net per million or in million XXXX, of XXXX.
primary OMIDRIA earned X the years difference and $XXX February the in between milestone is the again, million Here, in XXXX. XXXX received
million or was $X.XX compared per net of year share per a $XXX Our loss continuing full share for loss from to $X.XX XXXX XXXX. or million operations $XXX
So in for the meaning cash XXXX, year receipt $XX.X the positive of summary, $XXX company, in cash million million, XX, provided December milestone February which into flow the ended includes XXXX. for was operations,
of change quarter fourth and by Our in events. cash was for XXXX the investments significantly X affected
at million our million million outstanding million of repurchase of principal $X.X XXXX million maturity; to $XX value. second, to $X.X off used at X.X $X.X repurchase third, of our convertible shares stock. notes And notes First, common used used to XXXX convertible amount XX% pay par our
in quarter these not has included used fourth operations, X $XX.X million. which Our events cash was
additional at our we of payment investments from is cash approximately of As and February XXXX total in $XXX XX, debt million. operations XX, should fund to of March year, cash expected $XXX and this into $XXX and million December be XXXX. royalty sufficient XXXX, service investments, million This DRI the had with purchase
extends DRI since done without have with transaction deal shareholders, Omeros a effort our our dilution. of this XXXX financing not We runway most to protect consistent at and further dilutive August the recent
of program the X% In count. approximately the shares repurchase million also $X.X able fact, of reduced outstanding X of to XXXX, we've November shares XXXX reduction convertible through representing notes previously at the repurchase million noted, were a number outstanding our as par. an share of fourth share repurchase in we quarter, announcing XX% in since In
obtaining of priority, approval TA-TMA. FDA next our MASP-X corporate in narsoplimab to our Let's now inhibitor, turn
complete Consistent with since formal paths our of division, with year, in for As TMA pivotal and to dispute previously BLA, biologics data with developed XXXX submitted license receiving a with quarter on comparing of decision resolution we office FDA's external survival BLA. FDA's an of and our the new and letter fourth from that or FDA's subsequent The application, in formal review control. identified TA-TMA. analysis for review that potential from our the a discussed, followed for we've last data drugs late worked narsoplimab decision interactions resubmission survival plan trial response from FDA
continues and resubmission recommended covered with responded with those to FDA directed BLA. which round dialogue The with the elements of our rules, interactions review has regarding we formal provided meeting Each detailed a answers, successful by FDA FDA questions of to including duration. for
BLA for date for So I don't at an decision approval. this do, we we with date resubmission a related the have you or point, update. will When firm our provide
most the BLA. our completed of we've of sections waiting, While
marketing good to We're our authorization for on European narsoplimab also application for the progress Medicines Agency making TA-TMA. submission in
the satisfactory TA-TMA in an experts the Europe, off-label physicians regulatory in -- and treatment As in and a narsoplimab many believe truly patients or without without an often their approved TA-TMA advances for process even fatal continue with U.S. unpredictable confront condition both option. and to
volume access world trying to to from committed over use of increasing and or to TA-TMA narsoplimab these the both adult for patients. We treating program supplying all our physicians to request help compassionate continue pediatric receive We narsoplimab patients. an under expanded remain
narsoplimab failed in adults patients TA-TMA expanded ravulizumab, Total and/or endured who are XX We've them had defibrotide XXX other stopped cure with have specifically families the over transplant or previously by TMA. more these through have or their by regimens to children of ] treatment hope of a of from that one the cell Often insult pegcetacoplan. these agents, care of and followed treated access patients pediatric [ cancer, stem a only program. eculizumab, and taken
survival. narsoplimab So the about by the treatment, achieved of outcome, and to patients [ X-year date most of of yet a was common transplant one treated X/X date using those survival be them other after time who narsoplimab of metric achieved about have requested TMA previously half have poor ] from them been would year from expected receiving
both and are pediatric access treatment higher initial rates in and whose even Survival expanded only adult was narsoplimab. patients
saving XXX experts use. of of body at transplant directed compassionate adult So it under publication for been have narsoplimab and from of pediatric the Results preparing narsoplimab peer-reviewed access growing the TMA who over expanded manuscript a the of journals group congresses. and were peer-reviewed international A patients able to to is appears work our benefits adults. that certainly begun in international narsoplimab program in children have a access lives globally both publications reported and in
narsoplimab, mTOR then article published failed multi-organ and recent Sloan published be to XX%. journal Emory therapy, failed and treatment worsening X reported children from cellular of XX% infants, XX-year-old responded. with In is and X in Survival Memorial have transplantation involvement Investigators University X for maintain or eculizumab. a mTOR adolescents with with bone ] And were in has severe a these TA-TMA with had Center TA-TMA of to in the calcineurin to eculizumab Cancer the TA-TMA. inhibitors transplantation in step known use while further a report and time patient. a historically considered inhibitors withdrawal first potentiate the their TA-TMA. in marrow managing been to TA-TMA first allowing physicians are narsoplimab's the are known ability high-risk inhibitors describing complete response, [ cause to calcineurin patients than These less who treated Kettering achieve a and
is that used though they prevent transplant in life-threatening host stem are downside to disease withdrawing The these of GvHD. or graft agents cell versus
of TA-TMA of and potentially represent of to other the narsoplimab significant without to with lethal prevent treat to now narsoplimab GvHD their withdrawing would calcineurin a mTOR similarly GvHD. the management while TA-TMA. drug good and physicians We're inhibitors mortality. preventing risk The withdrawal treat results of maintaining the these the advance increases ability further to of use aware who TA-TMA allow So transplanters agents
X response the and a and at and Center Transplantation complete Cellular Transplant Research that patients of for February, to for treatment. TA-TMA Blood adult American narsoplimab International Therapy tandem meeting the demonstrated In Society the of presented Marrow X durable a reported poster and XXXX
X patients Median was of an The Research Marrow patients external authored of partial Institute, group of achieved a Arkansas Transplantation. X by response. The Sarah other Blood report investigators and across Cannon duration U.S. from the The treatment was Indiana and Vanderbilt, weeks. University
anemia. American transplantation Eculizumab subsequently XX with this eculizumab, XX% to mortality Day so multi-organ acute of a disease on treatment, septic narsoplimab start initiated patient abstract to on hemorrhage high-risk to the Diseases diffuse and kidney estimated in severe hemodialysis Day of aplastic Day who XX, late He was X. started Day Narsoplimab an was stem later developed old the days allogeneic TA-TMA. refractory man severe patient XX. was underwent XX, hospital Despite the XX% cell initiated for narsoplimab. a developed an was Journal disorder, recently, Kidney disorder. for who lung XX-year On published Most alveolar on tubular the of responded necrosis, described
in So that I certainly continues that are is to showing the patients. results and mount is narsoplimab think good the TA-TMA evidence conclusion we drawing
now third Turning our to priorities. the key of
inhibitor X potentially life-threatening rare complement in We ongoing to MAP-X disease. kidney continue of or OMSXXX, alternative diseases disease to PNH hemoglobinuria blood indications, targeting pathway glomerulopathy advance CXG, Phase or and a through life-threatening multiple our studies the nocturnal complement and of II the paroxysmal debilitating
our contrast for program has a narsoplimab a of no approved. in nature, which development by drug mechanism to for its a novel drug with TA-TMA, disease endpoints requires for which, been In novel clinical the
those potential has benefits inhibitors into affording for is and alternative important therapies. several pathway Our not OMSXXX other advantages of reasons. meaningful by and the patients following development shared program physicians other This
of has already demonstrating the been the already OMSXXX. diseases. the treatment agents a of clinically validated potential First, for by alternative therapeutic other of number inhibition Thereby pathway mechanism of value
III to potential other the we're development. be established inhibitors our follow designing clinical will advantages other Phase development trials trials, our able alternative we pathway agents. the road designing the And complement market over in clinical of on Second, the targeting clinical in map to or through third, demonstrate
detailed inhibitors and versus what have by in PNH in MAP-X We atrophy and OMSXXX CXG the has nephropathy. in also validated either and other alternative and other development. in we Beyond therapeutics alternative we clinically or pathway differentiators between previously approved see clinical programs, targets major inhibition as ongoing IgA geographic which been pathway have alternative pathway
levels inhibitors, MASP-X Number Briefly, body's targets. number has and MASP-X an relative fighting when and shown infection CX unlike alternative CX very examined acute B, Factor low ability. been not CX and other has CX circulating the to be one, a reactants maintain inhibitors phase to two, native unlike pathway
patient's should of OMSXXX maintain a B, targeting protection result, a MAP-X underlying CX inhibition than breakthrough life-threatening consistent more As CX or against potentially providing factor of disease. better drugs
convenience, X local and options administration. up every X patient and advice And by subcutaneous quarterly leaders, we're and In regimens in advantage deliver their development. other a of exploring competitors should physicians once to number opinion fit weeks response standards as the or set allowing result, OMSXXX patients by providing three, to from on better key intravenous treatment compliance and to offered inhibitors weeks, alternative XX pathway every and a no the preferences and market to
a day danicopan, trial, for combination the Factor D PNH MASP-X improved the by FDA inhibitor D is combination CX an less of danicopan frequent in the subcutaneous CX that is pill of or the remove infusion. was oral should CX efficacy to today, in medication that daily OMSXXX that Xx approved Clinical a taken every inhibits addition any the required enzyme means on over Just with IV the top X to of danicopan be or This shown target. was and question of activates significantly the a times efficacy needs OMSXXX. MASP-X a Factor inhibitor inhibition with alone. of inhibitor. likely frequent treatment Danicopan
This of every hemolysis. extravascular X dosing $XXX developed dosing validate with like again, the burden In asset. Jefferies should a and weeks comparison, today significant This and just expected substantial a is at of annual CX value and therapy represents sales more fact peak estimating potential issued patient to worldwide a the on is XX-week companion further and the or risk regimen danicopan monotherapy million. cost being Notably, every ravulizumab. convenient OMSXXX noncompliance Group have of Research dosing. of breakthrough OMSXXX report required single-drug top OMSXXX our the This, projection that as a of eculizumab inhibitors
the Phase to high, for of convened as fully of including our data. their have and of through we for proceeding design. Our and program, ongoing clinical comprised details experts discuss interest into PNH Currently, Phase analysis forward studies, of protocol in advisory have and advisers' we international both board II look III last well. OMSXXX uniformly we We is PNH evaluating reported our enthusiasm enrolled are treatment are of PNH now our program The and positive Phase to week OMSXXX an which interim ongoing III which program. move both X and guidance
should dosing. dose our final the PK/PD these studies study information ongoing PNH our to patients from in Data healthy in subjects necessary and from determine higher III provide Phase
and with trial hemoglobin Our levels newest in Phase enrolled portion Data [ a from OMSXXX and hemoglobin XX The interim to in weeks for of PNH improvements total both prespecified patients. demonstrated ] with patients with mean combination therapy. design provide core clinical our absolute OMSXXX, response has XX is OMSXXX II therapy. who therapy patients combination the study fully with analysis enrolled ravulizumab in a to data to trial combination The the ravulizumab from an meaningful reticulocyte therapy have then rapid response evaluating X-week had monotherapy patients the of and who and a statistically come added clinically response unsatisfactory trial's CX provided of OMSXXX count inhibitor, receiving switchover combination significant ravulizumab. show
in from will Congress European of OMSXXX been good hemolysis Response was monotherapy, Association, interim assessment sustained the addition pathway interim with inhibitor, Week to prevent is substantial which Full XX, The ravulizumab for experiencing analysis June. in at have occur on prior expected. These tolerated while for as the OMSXXX patients that interim safety the extravascular the Hematology or was a latest analysis profile. extravascular presentation which of hemolysis details data cutoff. alternative demonstrate the well EHA, submitted analysis the
of until available those Interim embargoed will in naive updated by the interim switchover patients online, our as EHA that details As PNH II congresses, were clinical at a analysis be oral with occur from one published this inhibitor of Hematology, the of all in featured presentations portion who Annual year. presentation data expected trial are or trial new previously are and Congress our from and mid-May. the complement American analysis not an submissions the almost data accepted other been ASH. are have December, treated this In Society or international monotherapy evaluating OMSXXX, with Phase later of to
Clinically benefits the size in marrow myelodysplastic in as this PNH OMSXXX cited in and effects and baseline others bone analysis, of hemoglobin, X and all X grams XX did red cell condition reported. patients reticulocyte meaningful beneficial observed patients of hemoglobin, failure. XX latest absolute increases who syndrome, at have All blood LDH, by deciliter, LDH, absolute those clone achieved changes per greater deciliter. on grams Consistent field. were patients working achieved of In in a normal causing were hemoglobin from enrolled hemoglobin all least X than in level Notably, a mean an not also count. per
All of X at per milligrams these kilogram subcutaneously every X a patients OMSXXX once were treated weeks. with dose of
enrolling from After this BLA identifying support submission focus observing X-week XX-week protocol for from amended II doses on the patients. OMSXXX that the and safety collect study, OMSXXX Phase from began of OMSXXX breakthrough efficacy the future efficacy directly the for the without hemolysis extension provide into in protection we data the to both a study treatment. a II PNH trial PNH, in naive an switchover To and trial, we duration. Patients break long-term in patient extension Phase roll or study either to in
to in provided proposed on input clinical Phase sufficient our to is in February, Phase our data Phase and design program for scope studies Dosing study support FDA and discuss we for BLA BLA and III requested a III dosing PNH. development program studies for nonclinical the extension submission. support in underway. with studies input and the met OMSXXX confirmed expectations presented PNH. FDA the that on and is In of of to nonclinical already We've III
trial We will approach year the to again BLA submission. discuss FDA design this details with our to Phase III and meet later further
As discuss part present Phase III of have PNH, will requested clinical a regulators and which development. our data and we available European strategy with meeting for at OMSXXX we European and nonclinical
Moving on being clinical in open trial patients screened. multiple our to in are countries Phase sites CXG, OMSXXX and are II evaluating now
in we choice the provide discussed, relevance III learned on anticipate This alternative a design but program. estimate in As pathway previously III in a the CXG XXXX. reporting the Phase the better CXG program. with amend of the Novartis inhibitor press dose first III should changing information protocol, based chose We of in initiation effect study study treatment in of release PNH B. part our in Phase for the positive Phase a resulted initiation, pathway Notably, delay validated iptacopan, Factor targeting alternative the of was by Novartis' a to
to We our Phase expect II in enrollment CXG trial begin this month.
all spent our established on multiple from pathway a the data potential well-differentiated to believe proceeding development we drug been a have over an to a this alternative was we development. diseases. purpose are today market upcoming the II under-recognized consistently The our with in value has ongoing clinical or we've studies inhibition the positive, trials. been that accrue is clinically that of in in pathway So advantages presents across a and you on number that provide has PNH better by validated substantial believe time through continues of the been Phase we short, pathway II the Phase what inhibitors ongoing alternative And Value of amount community. good understanding In OMSXXX and program. Phase update III with investment
the of the first-line and host diseases. pathway OMSXXX alternative For these treatment could standard become believe reasons, other a that for PNH care of of we
agents Phase pathway outset the findings turn targeting and key our discuss and today's the OMSXXXX. our identified last to IgA MASP-X briefly I'll the Now lectin to the III of the trial in of nephropathy call, priorities back family of at
III disappointing prespecified nephropathy As in interim narsoplimab a announced IgA last from a October, Phase analysis. we discontinued following outcome our ARTEMIS-IGAN trial
with of the narsoplimab proteinuria nephropathy proteinuria reduction that on did results consequently per primary external achieve call, patients discussed pathway greater data. III trial further adequate at trial Together and earnings weeks meaningful concentrations statistical in over patients grams with we endpoint day. show Phase of reviewed and unexpected inhibition. Top experts, did than not our not the effect. the not significance trial's During of the narsoplimab that reach baseline substantial IgA lectin we XX last plasma sustained in analyses did many placebo achieve and PK/PD line X placebo sustained levels indicate
in whose a to and quarterly the of renal OMSXXXX we're disease identify driven would would in any enable expect corporate been other it This nephropathy evaluate or in implicated with Once part any fourth dosing more chronic evaluating or trial. parallel is problem. renal which continues pathway to with expected In pathway or has specifically to biomarkers our Work series should enrichment in of our avoid for with be population chronic study in appears by consistent IgA due to disease. one hyperactivation. we episodic patients the we OMSXXXX, dosing to priority, indications selective be the decide inhibitor MASP-X lectin pathogenesis of disease value to this large that
dosing has successfully dose I a study either intravenously. OMSXXXX supporting quarterly single administered once Phase or subcutaneously ascending completed
dosing data Phase study and is multiple read out The of on expected completed that of second OMSXXXX later recently ascending half quarter. dose to program I this
for One macular indications neovascular market considering also degeneration, wet of that is are OMSXXXX large age-related known as AMD. the we
that previously demonstrated and have studies model. preclinical We efficacy [indiscernible] reported a well-established
produced only without chamber benefit X administration the back the intravitreal Since therapeutic to as evaluate inhibition MASP-X could eye. into wet in MASP-X a as clinical all These model the provide quickly the intravitreal need injections primate for To are and injections AMD every systemic frequently are or injections, Notably, as liver, moving in EYLEA Lucentis treatments meaning program, such weeks. required is a approved require of further of we wet injections. derisk AMD.
and game and or their targeting -- Phase quarter select next other intravenous a OMSXXXX. infusion indications their patients to an maintain potential In injection site both II words, the to physicians. avoid may injections for or eyes, subcutaneous both changer allow We're patients in
priorities, accelerating OMSXXXX the and has way extending trials runway X year. of So others well on achieved one in corporate cash our program, III achieving to nondilutively into and XXXX this narsoplimab we the II been OMSXXX Phase Phase our approval, already initiating are an
relatively advancing a investment Development across shareholder other add that is to series modest through value. programs believe meaningfully of also we
COVID-XX For of complement in or distress in groups, narsoplimab growing the of acute respiratory pathway demonstrating in numerous published syndrome ARDS, research [indiscernible] the volume journal and/or lectin ARDS. articles a including role
is being one finalized Another of the for showing submission. in This manuscript infection. therapeutic animal an benefits Haemophilus of inhibition model MASP-X severe
narsoplimab assessing criteria like suited There's diagnostic drivers COVID. well that for is and mounting clinical and headway diseases might in ARDS, challenges the COVID therapeutic acute evidence be address requiring lectin standardized of hospitalization. identifying and The approaches to making MASP-X are lack long also particularly in well endpoints, the in pathway a we're of long indications important these.
the assay, sensitive CX complex, proprietary, we have developed for development completing severe for ARDs. our commercialization. The is we've hyperactivation. measurement discriminate who specific well requiring marker moderate recognized ARDS patients pathway between also COVID-XX-related the need and or for options potential and such a COVID-XX parallel, mild evaluating assays use There's lectin identify MASP-X core hospitalization. highly in are a those an COVID other and The can has as inhibitor of as disease-related In and and assay that platform assay long its an
Turning inhibitor to program. our orally MASP-X administered
our and Omeros for blocker, subcutaneous new investigational lectin MASP-X franchise therapy first-line OMSXXXX an of filing intravenous the enable both control to to our oral narsoplimab, of expect inhibitor application. testing and pathway-related we complete drug will advance The long-acting enable chronic to acute continue diseases. We
animal first compulsions next to now on receiving or opioids, late of efficacy program OMSXXX disorder. predictive study the standard studies clinical disorders. cocaine, National are With is eating, year. success this both Drug cocaine well the and use year alcohol movement and expected to double-blind human funding nicotine, binge Let's across our inpatient well-established cocaine NIDA, models in our addiction treatment development requested randomized, for of is on Toxicity move cocaine assuming trial treatment as targeting inhibitor toxicology and primates of for to showing addictions as and slated PDEX OMSXXX, and as OMSXXX, support Institute and a begin Abuse, data
I in and these vitro, and components our information. been immuno-oncology For positive and earnings with our LID XXXX detailed call. with at cellular out. Emory often November adaptive touch of the To dyskinesias millions and nearly has described as review, again, T have elucidated studies levodopa-induced Parkinson's mapped X vivo movements vaccines using more involuntary immunomodulators, in L-DOPA, human our therapy, crippling so rates. were ultimately advantages of function further there that in platforms, wrap University franchise. studies And that Oncotoxins. those, a strong primate refer signaling and OMSXXX occur proprietary of the and with corporate August August and you To animal in patients been all on antigen-driven the therapeutics immuno-oncology platforms or treated up briefly I'll were both response The X our for immunomodulators investigators data cell CAR-T, November development indicate calls, number ex driven earnings of performed potential would date,
new our confirm and across continue we data generate our So to to franchise. results I-O
advance pace, we Officer, of year. now results. our on half the our that more be much Accounting call a in Chief through of this continues Jacobson, of go share progress expect financial Assuming these our to detailed Mike able over to I'll Mike? to the discussion to turn data second to
